Abstract 284P
Background
Follicular Lymphoma (FL) is known to be a disease of the elderly and younger patients are postulated to have distinct tumor biology and treatment outcomes. Various lymphoma groups across the world have studied this to understand if young adults (YA) need a different treatment approach. Our study fills the void in paucity of data from an Asian country on YA versus older population of Follicular Lymphoma.
Methods
The records of patients presented at our center between 2012 and 2018 were retrospectively reviewed. They were stratified by age into ≤40 (YA) and > 40 years and their demographics, clinicopathological features and outcomes were analyzed.
Results
A total of 167 patients of follicular lymphoma were identified with 24 (14.3%) patients belonging to YA group. A final analysis of 154 patients is presented after excluding patients with upfront Grade 3b disease. Median age in YA and older patients was 37 and 55 years respectively. YA group had a higher incidence of extranodal involvement, bone marrow involvement, and advanced disease at presentation, whereas high LDH and low hemoglobin levels were more common in older patients. As per FLIPI risk scoring, 43% of our patients in both groups had high-risk disease. All YA received treatment upfront, while 7.7% of older population underwent observation. Most commonly used chemotherapy regimen was CVP and 46% of our patients received Rituximab. The ORR was significantly more in YA population (91.3% vs 83.2%) At a median follow-up of 3.5 and 3.2 years (YA and >40 years respectively), YA had a better median PFS (3.5 yrs) and OS (5.9 yrs) compared to those older than 40 (PFS 3.1 yrs, OS 5.2 yrs). On multivariate analysis, normal LDH, lower FLIPI score and use of Rituximab were associated with a significantly longer PFS in older patients, however, it showed a trend towards improved PFS in young adult population that did not reach statistical significance. No parameter showed a significant association with OS.
Conclusions
YA more frequently present with advanced stage requiring upfront treatment, however they exhibit higher ORR and better PFS and OS compared to older counterparts. The survival rates seen are comparable to another Indian study but lower than the Western data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract
YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
Presenter: Yanping Chen
Session: Poster display session
Resources:
Abstract